A Phase 4 interventional study of Suzetrigine in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.
Among the 10 studies testing suzetrigine in Acute Pain, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 5th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Soheil Ashkani Esfahani
Ages 18–75
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2025.
This study's enrollment of 100 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 165 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 9th registered.
Vertex Pharmaceuticals Incorporated’s Acute Pain studies by the year they started, since 2017.
2 of the studies testing suzetrigine in Acute Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
| NCT07795827Soheil Ashkani EsfahaniSuzetrigine for Postoperative Pain After Total Ankle Replacement | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing suzetrigine in Acute Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 10 in Acute Pain:
This tab as a report to print or save as PDF → With an account.
The study evaluates the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SUZ 100 milligram (mg) as the loading dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first.
Drug: Suzetrigine
Tablets for oral administration.
Also known as: VX-548, SUZ, JOURNAVX
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as poor, fair, good, very good or excellent. Percentage of participants who reported good, very good or excellent on the PGA scale was reported.
Time frame: Day 14 or at Pain Resolution, whichever occurs first
| Milestone | Suzetrigine (SUZ) |
|---|---|
| Started | 100 |
| Mfas | 99 |
| Safety set | 99 |
| Completed | 93 |
| Not completed | 7 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawal of consent (not due to ae) | 1 |
| Withdrew: Other | 1 |
| Withdrew: Enrolled but not dosed | 1 |
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as poor, fair, good, very good or excellent. Percentage of participants who reported good, very good or excellent on the PGA scale was reported.
| Percentage of Participants | Suzetrigine (SUZ) |
|---|---|
| Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment | 90.7 (83.1 to 95.7) |
Collected over Day 1 up to Day 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Suzetrigine (SUZ) | 0/99 (0%) | 3/99 (3%) | 21/99 (21.2%) |
| Event | Suzetrigine (SUZ) |
|---|---|
| BradycardiaCardiac disorders | 1/99 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/99 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/99 |
| Event | Suzetrigine (SUZ) |
|---|---|
| NauseaGastrointestinal disorders | 11/99 |
| Blood creatine phosphokinase increasedInvestigations | 8/99 |
| Procedural nauseaInjury, poisoning and procedural complications | 6/99 |
All participants who have received at least 1 dose of study drug, excluding participants who meet one of the postoperative individual stopping rules before discharge/leaving the medical facility.
| Age, Continuous(Years) | Suzetrigine (SUZ) |
|---|---|
| Mean | 41.2 ± 10.5 |
| Sex: Female, Male(Participants) | Suzetrigine (SUZ) |
|---|---|
| Female | 91 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Suzetrigine (SUZ) |
|---|---|
| Hispanic or Latino | 35 |
| Not Hispanic or Latino | 63 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Suzetrigine (SUZ) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 34 |
| White | 63 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Ran from Mar 2025 to primary completion in Oct 2025, 7 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →